Merck expands capacity for Antibody Drug Conjugate (ADC), therapies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated